Begin main content

Emtricitabine/Tenofovir for Post-Exposure Prophylaxis Against HIV: A Review of Clinical Effectiveness and Cost-Effectiveness

Last updated: March 17, 2017
Project Number: RC0868-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of emtricitabine/tenofovir, with or without integrase strand transfer inhibitors, compared with alternative antiretroviral drug regimens for post-exposure prophylaxis against HIV?
  2. What is the cost-effectiveness of emtricitabine/tenofovir, with or without integrase strand transfer inhibitors, compared with alternative antiretroviral drug regimens for post-exposure prophylaxis against HIV?

Key Message

Limited low-quality evidence suggested that patients prescribed a tenofovir-based two or three-drug regimen were more likely to adhere to post-exposure prophylaxis (PEP), or complete the prescribed PEP regimen, than those prescribed a zidovudine-based two or three drug-regimen. Very limited low-quality evidence suggested that a tenofovir based on wo or three-drug regimen was associated with lower discontinuation rates of PEP due to adverse events as compared with zidovudine-based regimens. HIV seroconversion was rare in the PEP population, and an association with PEP regimen was not determined. Cost-effectiveness studies in the PEP population were not identified.